Royalty Pharma (RPRX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Royalty Pharma (RPRX) is Moderate Outperform.

The composite score behind that read is +0.27, weighing +0.35 of bullish evidence against -0.04 bearish.

Royalty Pharma last closed at $56.93, +1.28% on the session.

Against the IVW growth benchmark the position is +0.48% over the forecast window.

The read is built from 15 underlying insights — 12 bullish and 3 bearish.

Agreement across those insights is 80%.

Royalty Pharma has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Royalty Pharma in the 29th percentile on valuation and the 66th percentile on return on equity, where 100 is best.

Royalty Pharma is classified under Health Care / Pharmaceuticals, with a market capitalisation of $32.32B.

StockMap tracks Royalty Pharma as the 13th largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Royalty Pharma ranks 7th of 151 in the group, against a group median of -0.08.